USPTO serial 79406403
QIACUITYDX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 14, 2025
- Examiner
- CASTRO, GIANCARLO
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with QIACUITYDX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
G MATHEW LOMBARD
G MATHEW LOMBARD LOMBARD & GELIEBTER LLP1325 AVENUE OF THE AMERICAS28 FLOORNEW YORK, NY 10019Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic preparations for medical or veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposes, in particular diagnostics, for marking, amplifying, quantification and/or for the analysis of biopolymers, in particular nucleic acids; chemical, biochemical and biotechnological preparations for medical and veterinary purposes, in particular reagents, enzymes and buffer solutions for marking, amplifying, quantification and/or for the analysis of biopolymers, in particular nucleic acids, in particular reagents, enzymes and buffer solutions for nucleic acid amplification; kits containing preparations for medical and veterinary diagnostic purposes, in particular for marking, amplifying, quantification and/or for the analysis of biopolymers, in particular nucleic acids, in particular reagents, enzymes and buffer solutions for nucleic acid amplification; chemical reagents for medical purposes; cartridges containing medical diagnostic reagents for use in Polymerase Chain Reaction (PCR) or digital Polymerase Chain Reaction (PCR) instruments; medical diagnostic assays for testing of body samples, including bodily fluids and tissue in the detection, monitoring, and prediction of disease or other conditions, disease states, hormone level, drug level, drug response, organ function effectiveness, and clinical response; diagnostic test kits comprised of medical diagnostic reagents and assays for testing in the field of medical diagnostics. | ACTIVE | — |
| 010 | Apparatus for medical and veterinary diagnostic analysis and determination of medical and veterinary conditions, namely DNA and RNA testing apparatus; Medical and veterinary equipment for diagnostic purposes; clinical medical laboratory apparatus and analytical instruments, namely digital Polymerase Chain Reaction (d PCR) instruments for use in in-vitro and in-vivo diagnostics; medical devices for detection of infectious disease, namely, digital polymerase chain reaction (dPCR) platforms; medical devices for use in pre-natal screenings, namely, digital polymerase chain reaction (dPCR) platform; medical devices, namely, digital polymerase chain reaction (dPCR) instruments for use in detecting, diagnosing and treating cancer and infectious disease, namely, digital polymerase chain reaction (dPCR) platform; medical devices, namely, digital polymerase chain reaction (dPCR) instruments for use in pre-natal screenings, namely, digital polymerase chain reaction (PCR) platform; medical devices, namely, instruments for use in measuring and quantifying copy number of DNA for medical diagnostic purposes, namely, digital polymerase chain reaction (dPCR) platform; microfluidic plates for use as medical apparatus. | ACTIVE | — |
| 044 | Testing services, namely, quantifying DNA and RNA for medical, diagnostic and treatment purposes; rental of digital Polymerase Chain Reaction (PCR) apparatus; RNA or DNA analysis for cancer diagnosis and prognosis; Medical services, in particular medical analysis in connection with the treatment of individuals; providing information in the fields of medicine, veterinary medicine and pharmaceuticals; health centers, namely, genetic centers providing medical diagnostic, preventive and curative therapy services for genetic disorders, cancer treatment centers, rare disease treatment centers, children's hospitals and women's hospital; medical clinics; gene therapy services in the field of oncology, infertility, prenatal diagnostics, carrier testing, and genetically inherited diseases; medical laboratory services for the analysis of samples taken from patients. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by QIAGEN GmbH
- Other trademarks owned by QIAGEN GmbH
- Other trademarks owned by QIAGEN GmbH
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 044
- Similar marks named QIACUITYDX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 7, 2026 | FINV | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 23, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 22, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 26, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 9, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 9, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 14, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 14, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 14, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 26, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 26, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 20, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 23, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 16, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 16, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 16, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 29, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 11, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 11, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 23, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 22, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 13, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 13, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 13, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 10, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |